Bersanlimab (BI-505) 是一種全人源單克隆抗體，靶向細(xì)胞間粘附分子-1 (ICAM-1 或 CD54)。Bersanlimab 具有抗癌作用

武漢佰樂(lè)博代理：Research Grade Bersanlimab

貨號(hào)：DHC16001

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75477.html

產(chǎn)品購(gòu)買聯(lián)系方式：027-65279366

產(chǎn)品介紹：Bersanlimab (BI-505) 是一種全人源單克隆抗體，靶向細(xì)胞間粘附分子-1 (ICAM-1 或 CD54)。Bersanlimab 具有抗癌作用。

通用名:Bersanlimab

純度:>95% by SDS-PAGE.

濃度:1mg/ml

Formulationicon:0.01M PBS, pH 7.4.

內(nèi)毒素:Please contact with the lab for this information.

別名:BI-505

靶點(diǎn);物種:Human CD54/ICAM1

種類；Homo sapiens

受體鑒定：IgG1-lambda

CAS: 1987854-08-9

存儲(chǔ)條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻(xiàn)：

Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. PMID: 27136449

Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature. PMID: 27532314

Self-management interventions for people with chronic obstructive pulmonary disease. PMID: 35001366

Efficacy and safety of core stability training on gait of children with cerebral palsy: A protocol for a systematic review and meta-analysis. PMID: 31914039

What is "quality of evidence" and why is it important to clinicians? PMID: 18456631

Socioeconomic status and health: what we know and what we don't. PMID: 10681884

Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. PMID: 18483053

Acupuncture for heart failure: a Bayesian network systematic review and meta-analysis protocol. PMID: 34763474

研究應(yīng)用：CD38是一個(gè)經(jīng)過(guò)充分驗(yàn)證的治療多發(fā)性骨髓瘤的靶點(diǎn)。雖然抗cd38單克隆抗體治療使多發(fā)性骨髓瘤患者獲得了顯著的緩解，但仍有相當(dāng)一部分患者未能緩解，幾乎所有患者最終均復(fù)發(fā)。部分耐藥機(jī)制與CD38表達(dá)下調(diào)有關(guān)。此外，CD38廣泛表達(dá)于正常的淋巴細(xì)胞、髓細(xì)胞以及紅細(xì)胞(rbc)。為了有效地靶向腫瘤細(xì)胞上的CD38，我們假設(shè)針對(duì)腫瘤相關(guān)引導(dǎo)抗原(TAG)和CD38的雙特異性抗體可以實(shí)現(xiàn)腫瘤特異性并提高效力。ICAM-1是一種免疫球蛋白樣細(xì)胞黏附分子，在多發(fā)性骨髓瘤、淋巴瘤和部分實(shí)體瘤中高表達(dá)。抗ICAM-1抗體bersanlimab (BI505, BioInvent)耐受性良好，但對(duì)MM患者的臨床療效有限。我們制備了不同格式和幾何形狀的雙特異性CD38 x ICAM-1抗體，并比較了它們對(duì)CD38低表達(dá)和中表達(dá)icam1高的腫瘤細(xì)胞的體外活性。我們的研究結(jié)果表明，非對(duì)稱1+1格式對(duì)ICAM-1CD38+培養(yǎng)基或ICAM-1CD38+低表達(dá)細(xì)胞均具有較強(qiáng)的ADCC和ADCP活性。Fc修飾進(jìn)一步提高了雙特異性抗體的ADCC活性。為了進(jìn)一步了解抗原密度的影響，我們測(cè)試了ADCC活性在一系列表達(dá)CD38和ICAM-1的骨髓瘤和淋巴瘤細(xì)胞系上的選擇。我們觀察到在CD38表達(dá)極低的細(xì)胞上有較好的ADCC活性。此外，我們發(fā)現(xiàn)，與雙價(jià)CD38抗體相比，雙特異性抗體減少了NK細(xì)胞的殺兄弟作用和紅細(xì)胞結(jié)合。最重要的是，CD38 x ICAM1雙特異性抗體在體內(nèi)骨髓瘤和淋巴瘤模型中顯示出有效的腫瘤抑制活性。這些研究提示CD38 x ICAM-1雙特異性抗體對(duì)淋巴瘤和多發(fā)性骨髓瘤有多種作用方式。